688506:SSESichuan Biokin Pharmaceutical Co., Ltd. Class A Analysis

Sichuan Biokin is trading around 228 CNY, which sits just above its 20‑day SMA (≈225) but well below the 50‑day (≈262) and 200‑day (≈313) averages, signaling a short‑term pullback within a longer‑term bearish framework. The RSI of 46 points to neutral momentum, while the MACD line has crossed above its signal, offering a faint bullish flare amid overall downside pressure. Volatility is elevated at roughly 61% over the past month, and trading volume has been on a decline, raising liquidity concerns. Fundamentally, the company posted a robust 40% revenue surge and enjoys an impressive 89% gross margin, yet operating margins are negative (‑8%) and earnings per share remain in the red at –3.15 CNY. The balance sheet shows abundant cash (≈5 bn CNY) but also a hefty debt load (≈4.3 bn CNY) resulting in a debt‑to‑equity ratio above 75%, and the price‑to‑book (≈16.7) and price‑to‑sales (≈37) multiples are starkly elevated. In this environment, the stock appears overvalued relative to its earnings and book value, while its growth narrative is tempered by persistent losses and high leverage.